abrdn Life Sciences Investors (abrdn Life Sciences Investors) Unearned Income

: $0.00 Mil (As of Sep. 2023)

View and export this data going back to . Start your Free Trial

abrdn Life Sciences Investors's Unearned Income for the quarter that ended in Sep. 2023 was $0.00 Mil.

abrdn Life Sciences Investors Unearned Income Historical Data

The historical data trend for abrdn Life Sciences Investors's Unearned Income can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

abrdn Life Sciences Investors Annual Data

Trend

Sep17

Sep18

Sep19

Sep20

Sep21

Sep22

Sep23

Unearned Income

abrdn Life Sciences Investors Semi-Annual Data
	Sep17	Mar18	Sep18	Mar19	Sep19	Mar20	Sep20	Mar21	Sep21	Mar22	Sep22	Mar23	Sep23
Unearned Income									-	-	-	-	-

abrdn Life Sciences Investors Unearned Income Calculation

Unearned Income is the income received but not yet earned, it represents the unearned amount that is netted against the total loan.

abrdn Life Sciences Investors Unearned Income Related Terms

Thank you for viewing the detailed overview of abrdn Life Sciences Investors's Unearned Income provided by GuruFocus.com. Please click on the following links to see related term pages.

abrdn Life Sciences Investors (abrdn Life Sciences Investors) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Financial Services » Asset Management » abrdn Life Sciences Investors (NYSE:HQL) » Definitions » Unearned Income

Comparable Companies

Traded in Other Exchanges

N/A

Address

1900 Market Street, Suite 200, Philadelphia, PA, USA, 19103

Website

https://www.abrdnhql.com

abrdn Life Sciences Investors operates as a non-diversified closed-end management investment company. Its investment objective is to seek long-term capital appreciation by investing primarily in securities of Life Sciences companies. It invests in securities of public and private companies that are believed by the Fund's Investment Adviser, abrdn Inc to have significant potential for above-average growth.

Executives

Todd Reit	director	C/O ABERDEEN STANDARD INVESTMENTS, 1900 MARKET STREET, SUITE 200, PHILADELPHIA PA 19103
Bill Maher	director	600 WEST BROADWAY, 30TH FL., SAN DIEGO CA 92101
Rose Dimartino	director	C/O ABRDN, 1900 MARKET STREET, PHILADELPHIA PA 19103
James Joseph O'connor	other: Director of Adviser	C/O ABERDEEN STANDARD INVESTMENTS, 1900 MARKET STREET, SUITE 200, PHILADELPHIA PA 19103
Marika Tooze	other: Director of Adviser	C/O ABRDN, 1900 MARKET STREET, SUITE 200, PHILADELPHIA PA 19103
Aberdeen Standard Investments Inc.	other: Adviser	1900 MARKET ST., 2ND FLOOR, PHILADELPHIA PA 19103
Jaclyn Marie Matsick	other: Director of Adviser	C/O ABRDN, 1900 MARKET STREET, SUITE 200, PHILADELPHIA PA 19103
Lucia Sitar	officer: VP and Chief Legal Officer	1735 MARKET STREET, 32ND FLOOR, PHILADELPHIA PA 19103
Jennifer A Nichols	other: Director of Adviser	1735 MARKET STREET, 37TH FLOOR, PHILADELPHIA PA 19103
Christian Pittard	officer: President	ONE BOW CHURCHYARD, LONDON X0 EC4M 9HH
Megan Kennedy	officer: Secretary and Vice President	1735 MARKET STREET, 32ND FLOOR, PHILADELPHIA PA 19103
Sharon Ferrari	officer: Treasurer and CFO	1735 MARKET STREET, 32ND FLOOR, PHILADELPHIA PA 19103
Alan R Goodson	officer: Vice President	1735 MARKET STREET, 32ND FLOOR, PHILADELPHIA PA 19103
Joseph Andolina	officer: Chief Compliance Officer & VP	1735 MARKET STREET, 32ND FLOOR, PHILADELPHIA PA 19103
Stephen Bird	director	388 GREENWICH STREET, 17TH FLOOR, NEW YORK NY 10022